Precision Medicine: Opportunities and Challenges for Clinical Trials
Challenges in Clinical Trials Networks
-
Upload
us-cochrane-center -
Category
Health & Medicine
-
view
835 -
download
2
Transcript of Challenges in Clinical Trials Networks
![Page 1: Challenges in Clinical Trials Networks](https://reader035.fdocuments.net/reader035/viewer/2022062312/55622438d8b42ab6588b4d84/html5/thumbnails/1.jpg)
1
Challenges for Clinical Trial Networks
![Page 2: Challenges in Clinical Trials Networks](https://reader035.fdocuments.net/reader035/viewer/2022062312/55622438d8b42ab6588b4d84/html5/thumbnails/2.jpg)
2
Modern Day Challenges in Clinical Trials
• How do we collaborate with industry?• Who controls study design? data? analysis?• Who controls which patients go to which
clinical trials? Minimize bias/conflicts• How do we control financial conflicts of
interest with human subjects research?• How do we control authorship? spin?• How do we do trials intelligently, efficiently,
cost-effectively, and ethically?
![Page 3: Challenges in Clinical Trials Networks](https://reader035.fdocuments.net/reader035/viewer/2022062312/55622438d8b42ab6588b4d84/html5/thumbnails/3.jpg)
3
Evolution of Randomized Clinical Trials in Retina
Evolution of Randomized Clinical Trials in Retina
21st Century: Networks for Randomized Clinical Trials in Retina
1950s: Single center trial – Patz et al
1970s: Multicenter clinical trials at university-based centers (e.g., DRS) 1970s: Multicenter clinical trials at university-based centers (e.g., DRS)
1980s: Multicenter clinical trials at university-based and community-based 1980s: Multicenter clinical trials at university-based and community-based centers (e.g., ETDRS)centers (e.g., ETDRS)
1990s: Industry sponsors randomized clinical trials (e.g., PDT trials) as 1990s: Industry sponsors randomized clinical trials (e.g., PDT trials) as other government-sponsored trials continue (e.g., AREDS, SST, CAPT)other government-sponsored trials continue (e.g., AREDS, SST, CAPT)
![Page 4: Challenges in Clinical Trials Networks](https://reader035.fdocuments.net/reader035/viewer/2022062312/55622438d8b42ab6588b4d84/html5/thumbnails/4.jpg)
4
When is a Network Indicated?What Should a Network Do?
• A network is of value when it is perceived likely that numerous treatments for a condition are on the horizon
• A network should have the efficiency of a common infrastructure to support multiple protocols
• A network should provide tremendous efficiency in timeline for protocol development to enrollment to completion, attractive to the public and industry
![Page 5: Challenges in Clinical Trials Networks](https://reader035.fdocuments.net/reader035/viewer/2022062312/55622438d8b42ab6588b4d84/html5/thumbnails/5.jpg)
5
What Is the Diabetic Retinopathy Clinical Research Network
(DRCR.net)?Dedicated to multicenter clinical research of diabetic
retinopathy, macular edema and associated disorders.
![Page 6: Challenges in Clinical Trials Networks](https://reader035.fdocuments.net/reader035/viewer/2022062312/55622438d8b42ab6588b4d84/html5/thumbnails/6.jpg)
6
DRCR Network Overview
• Objective:– Develop and operate a collaborative
network to facilitate multicenter clinical research on diabetic retinopathy, diabetic macular edema and associated conditions.
![Page 7: Challenges in Clinical Trials Networks](https://reader035.fdocuments.net/reader035/viewer/2022062312/55622438d8b42ab6588b4d84/html5/thumbnails/7.jpg)
7
Priority Initiatives
• Involvement of community-based practices, as well as academic centers
• Involve “new” investigators to train potential future leaders in randomized clinical trials
• Collaborate with industry to facilitate investigations and pursue opportunities otherwise not possible and to do so in a manner consistent with the Network’s dedication to academic integrity and optimal clinical trial performance.
![Page 8: Challenges in Clinical Trials Networks](https://reader035.fdocuments.net/reader035/viewer/2022062312/55622438d8b42ab6588b4d84/html5/thumbnails/8.jpg)
8
Maintaining Academic Integrity of Network: RCTs in 21st Century• Network controls study design/protocols
• Network controls budget (per NIH regs.)
• Network controls data
• Network controls publications and presentations
• Network controls organization and governance (within federal and local regulations)
![Page 9: Challenges in Clinical Trials Networks](https://reader035.fdocuments.net/reader035/viewer/2022062312/55622438d8b42ab6588b4d84/html5/thumbnails/9.jpg)
9
Current DRCR Network Status
• Overall Network Participation (as of January 15, 2008)
– 118 active or pending sites, 190 sites submitted application to the Network
– 75 community-based sites
– 322 total Investigators– 809 additional personnel– 33 States– >60 investigators served
on at least 1 committee
![Page 10: Challenges in Clinical Trials Networks](https://reader035.fdocuments.net/reader035/viewer/2022062312/55622438d8b42ab6588b4d84/html5/thumbnails/10.jpg)
10
DRCR Network Protocols (as of October 6, 2008) # of Subjects
Pilot Study of Laser Photocoagulation for DME (A) 263Randomized Trial: Intravitreal Steroids vs Focal Laser for DME (B) 693
Temporal Variation in OCT Measurements in DME (C) 107
Evaluation of Vitrectomy for DME (D) 237A Pilot Study of Peribulbar Triamcinolone Acetonide for DME (E) 113Observational Study: Development of DME After PRP (F) 155
Subclinical Diabetic Macular Edema Study (G) 82Phase 2 Randomized Trial of Bevacizumab for DME (H) 121Laser-Ranibizumab-Triamcinolone for DME (I) – Goal 701 618Laser-Ranibizumab-Triamcinolone for PDR + DME (J) – Goal 325 198Laser Response Protocol (K) 128
DRCR Network Study Subject Total 2,715
![Page 11: Challenges in Clinical Trials Networks](https://reader035.fdocuments.net/reader035/viewer/2022062312/55622438d8b42ab6588b4d84/html5/thumbnails/11.jpg)
11
Network Challenges
• How do you keep the investigators engaged and enthusiastic?
![Page 12: Challenges in Clinical Trials Networks](https://reader035.fdocuments.net/reader035/viewer/2022062312/55622438d8b42ab6588b4d84/html5/thumbnails/12.jpg)
12
DRCR Network Protocols (as of October 6, 2008) Protocol Chairs
Pilot Study of Laser Photocoagulation for DME (A) Fong
Randomized Trial: Intravitreal Steroids vs Focal Laser for DME (B) Ip
Temporal Variation in OCT Measurements in DME (C) Danis
Evaluation of Vitrectomy for DME (D) Haller
A Pilot Study of Peribulbar Triamcinolone Acetonide for DME (E) Chew
Observational Study: Development of DME After PRP (F) Brucker
Subclinical Diabetic Macular Edema Study (G) Bressler
Phase 2 Randomized Trial of Bevacizumab for DME (H) Scott
Laser-Ranibizumab-Triamcinolone for DME (I) Elman
Laser-Ranibizumab-Triamcinolone for PDR + DME (J) Googe*
Laser Response Protocol (K) Browning
DRCR Network Protocol Chair Totals 11
![Page 13: Challenges in Clinical Trials Networks](https://reader035.fdocuments.net/reader035/viewer/2022062312/55622438d8b42ab6588b4d84/html5/thumbnails/13.jpg)
13
Network Challenges
• How do you keep the investigators engaged and enthusiastic?– Involve investigators in “front”
(protocol development) and “back” end (writing committee) of protocols
– Keep actual day-to-day operations of clinical trial centralized
![Page 14: Challenges in Clinical Trials Networks](https://reader035.fdocuments.net/reader035/viewer/2022062312/55622438d8b42ab6588b4d84/html5/thumbnails/14.jpg)
14
Network Challenges
• How do you govern across wide environments, missions, cultures, personalities, at one time, and over time?
![Page 15: Challenges in Clinical Trials Networks](https://reader035.fdocuments.net/reader035/viewer/2022062312/55622438d8b42ab6588b4d84/html5/thumbnails/15.jpg)
15
DRCR Network Organization and Governance
DRCR Network Organization and Governance
Executive Committee (“Board of Directors”): provides oversight; sets policy; approves protocols
“Officers” Run Operations of NetworkCoordinating Center Principal Investigator (“CEO”);
Network Chair (“President”); Assistant Director (“COO”)
Investigators/staff(“Shareholders”)
NEIDSMC
![Page 16: Challenges in Clinical Trials Networks](https://reader035.fdocuments.net/reader035/viewer/2022062312/55622438d8b42ab6588b4d84/html5/thumbnails/16.jpg)
16
Network Challenges
• How do you implement new ideas rapidly?
![Page 17: Challenges in Clinical Trials Networks](https://reader035.fdocuments.net/reader035/viewer/2022062312/55622438d8b42ab6588b4d84/html5/thumbnails/17.jpg)
17
DRCR.net: From Idea to Protocol(Example of Bevacizumab for DME)
Idea Tabled:Reviewed
PeriodicallyIdea Declined
Executive Committee Reviews PRCR Reviews Monthly – Jan 2006
Disposition
Anyone may submit idea on DRCR.net Idea Form – Nov 2005
Protocol Concept Review Committee (PRCR) Reviews Ideas Monthly – Dec 2005
Idea Accepted:Protocol Development
Committee Created
![Page 18: Challenges in Clinical Trials Networks](https://reader035.fdocuments.net/reader035/viewer/2022062312/55622438d8b42ab6588b4d84/html5/thumbnails/18.jpg)
18
DRCR.net: From Idea to Protocol(Example of Bevacizumab for DME)
Idea Tabled:Reviewed
PeriodicallyIdea Declined
Executive Committee Reviews PRCR Reviews Monthly – Jan 2006
Disposition
Anyone may submit idea on DRCR.net Idea Form – Nov 2005
Protocol Concept Review Committee (PRCR) Reviews Ideas Monthly – Dec 2005
Idea Accepted:Protocol Development
Committee Created
![Page 19: Challenges in Clinical Trials Networks](https://reader035.fdocuments.net/reader035/viewer/2022062312/55622438d8b42ab6588b4d84/html5/thumbnails/19.jpg)
19
IRBs/clinicalsites need to
approve
Any industrycollaboration
may need approval
NIH External Protocol Review Committee Must Approve Protocol – Apr 2006
DSMC Must Approve Protocol – Apr 2006
Protocol Development Committee Creates Protocol – Feb 2006
Executive Committee Must Approve Protocol –Protocol Steering Committee Developed – Mar 2006
FDA or other regulatoryagencies may need
to approve
DRCR.net: From Idea to Protocol(Example of Bevacizumab for DME)
![Page 20: Challenges in Clinical Trials Networks](https://reader035.fdocuments.net/reader035/viewer/2022062312/55622438d8b42ab6588b4d84/html5/thumbnails/20.jpg)
20
Primary outcome complete October 2006
Follow-up completed November 2006Data finalized December 2006
Writing Committee completes draft February 2007Submitted March 2007, revised and accepted May 2007
Results published August 2007
Enrollment begins June 2006
Enrollment complete August 2006
DRCR.net: From Idea to Protocol(Example of Bevacizumab for DME)
![Page 21: Challenges in Clinical Trials Networks](https://reader035.fdocuments.net/reader035/viewer/2022062312/55622438d8b42ab6588b4d84/html5/thumbnails/21.jpg)
21
Network Challenges
• How do you manage multiple IRBs and contracts?– Community-based: encourage central
IRB; initial contract with amendments for each protocol
– University-based: participation only in studies enrollment anticipated to be 6 months or more if refuse central IRB and simple contract
![Page 22: Challenges in Clinical Trials Networks](https://reader035.fdocuments.net/reader035/viewer/2022062312/55622438d8b42ab6588b4d84/html5/thumbnails/22.jpg)
22
Network Challenges
• How do you maintain “public” support?
![Page 23: Challenges in Clinical Trials Networks](https://reader035.fdocuments.net/reader035/viewer/2022062312/55622438d8b42ab6588b4d84/html5/thumbnails/23.jpg)
23
Resources for the Scientific Community
• All protocols, policies, procedures, financial disclosures, and link to publications available on public www.drcr.net website
• Public documented dataset provided for use by other researchers via website when protocol complete
• Plans for access to genetic material matched to exquisitely characterized phenotypes
• Network open to community of retina specialists to participate in all aspects
• Community invited to submit protocol ideas
![Page 24: Challenges in Clinical Trials Networks](https://reader035.fdocuments.net/reader035/viewer/2022062312/55622438d8b42ab6588b4d84/html5/thumbnails/24.jpg)
24
Randomized Clinical Trials in Retina: From Single Center Studies in 1950 to Networks in
the 21st CenturyNew challenges in next 5 years for the DRCR Network: more protocols, international sites,
even more streamlined operations